to invent better
At DMC we’re developing a medical device platform that utilises our patented inhalation technology to deliver life-saving treatment in multiple emergency scenarios.
The first generation inhaler has been developed to provide emergency treatment of anaphylaxis by delivering epinephrine through inhalation.
RETHINKING HOW WE
The onset of symptoms can occur rapidly and include:
- Swelling or tightness of the throat
- Difficulty breathing or wheezing
- Swelling of the tongue, face, or lips
- Dizziness or unconsciousness
- Young children may become pale or floppy
- Hives or reddening of the skin
- Abdominal pain or vomiting
The most common triggers for anaphylactic shock include food, insect venom and medicines with the severity of reactions varying between individuals.
Epinephrine is the first line of treatment, rapidly reversing the effects of anaphylaxis.
The current standard is to administer the epinephrine via intramuscular injection as soon as possible. In a community setting this can be injected via an auto-injector, which is administered by the patient themselves or a bystander.
- The majority of consumers do not carry their auto-injectors regularly due to their size and storage requirements
- Parents/Caregivers and patients are hesitant to use their auto-injectors because of a fear of needles
- When auto-injectors are used, they are commonly misused leading to injury and poor treatment outcomes
- Time to peak plasma concentration is slow, on average absorption takes eighteen minutes.*
* In Phase 1 clinical studies testing inhalation delivery of DMC’s proprietary epinephrine formulation, plasma epinephrine concentrations reached Cmax 8 times faster compared to a widely used autoinjector.
ANAPHYLAXIS : THE UNMET CLINICAL NEED
just one exposure
*Two most commonly given responses
1 IN 4 PEOPLE TRY
PREVALENCE AND PRESCRIPTIONS FOR ANAPHYLAXIS IN THE USA AND EU
Epinephrine is the only drug used to treat severe allergic reactions including anaphylaxis. It’s commonly used via intramuscular auto-injector.
A report in the Journal of Allergy and Clinical Immunology (JACI) estimates that 1 in 50 residents in the United States may be at risk of an anaphylactic reaction. 1
It’s suggested that the prevalence could be even higher with The Allergy and Asthma Foundation estimating anaphylaxis occurs in about 5%, or 1 in 20 Americans. 2
IQVIA prescription data for auto-injectors in the USA estimates that approximately only 4 million people have a prescription.
Data from Europe suggests that around 4% of the general population has experienced an anaphylactic episode.
IQVIA prescription data for auto-injectors in Europe estimates that approximately only 10% of eligible people receive them.
According to the European Anaphylaxis Registry, less than 15% of anaphylaxis episodes are treated with an auto-injector.